Buccal Drug Delivery Market – Global Forecast to 2030 | By Type & Application

The global Buccal Drug Delivery market size is expected to be worth around US$ 8.9 billion by 2030, according to a new report by Vision Research Reports.

The global Buccal Drug Delivery market size was valued at US$ 6.8 billion in 2020 and is anticipated to grow at a CAGR of 10.2% during forecast period 2021 to 2030.

Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/38999

Report Coverage

Report Scope Details
Market Size US$ 8.9 billion by 2030
Growth Rate CAGR of 10.2% From 2021 to 2030
Base Year 2021
Forecast Period 2021 to 2030
Segments Covered Type, Application, End-user
Regional Scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Mentioned Teva Pharmaceutical Industries Ltd.; Pfizer Inc.; GlaxoSmithKline plc; Indivior Pharmaceuticals; Generex Biotechnology; Catalent; ARx LLC; BioDelivery Sciences International, Inc.; Cynapsus Therapeutics Inc.; Endo Pharmaceuticals plc

Growth Factors

Buccal drug delivery systems have gained significant momentum since the last decade. Elimination of first-pass metabolism, quick absorption of the pH-sensitive drug, no interaction with stomach acid, quicker onset of action than any oral dose, minimal side effects, and reduced drug degradation are some of the factors fueling the market growth. Buccal drug delivery has gained large acceptance among geriatric patients and patients having difficulty swallowing.

Buccal drug delivery systems have gained significant growth potential due to constant research and development in this field. Compared to oral dosage form, buccal delivery is considered the most convenient and preferred choice, especially among geriatricpatients. This drug delivery route ensures elimination of first pass metabolism, allowing drugs thatarepH sensitive and easily degraded to be administered effectively.

By Type Analysis

The buccal tablets and lozenges segment captured the largest share of over 45.0% in 2020. Increased consumer acceptance, ease of formulation, cost-effectiveness, and wide availability of drug candidates for formulation are the factors responsible for the segment growth.

The sublingual films segment is expected to grow at the highest rate during the forecast period. Factors such as immediate availability of high concentration of drug at a target site and increased research to develop controlled release formulation are responsible for the high growth of the segment.

By End-user Analysis

The hospitals segment dominated the market with a share of over 40.0% in 2020. Increased admission in hospitals, especially of geriatric patients, the abundance of emergency care supplies, and product development and research by various community hospitals are the reasons behind this segment growth.

3 community hospitals in Japan conducted in vitro and in vivo studies to develop mucoadhesive microparticle-laden gels for oral mucositis. The result confirmed the high concentration of the drug at the target site and quicker treatment than traditional dosage forms are likely to improve the adoption.

By Application Analysis

The smoking cessation segment accounted for the largest share of over 31.0% in 2020. Buccal drug delivery is often the most preferred and effective formulation for treating patients with smoking or nicotine addiction.

Increased research to treat sudden cardiac arrest outside hospitals and growing adoption of immediate treatment options have improved the acceptance of sublingual tablets, films, or even injections. This is responsible for the highest growth rate of the angina pectoris segment.

By Regional Analysis

North America dominated the market with a revenue share of over 31.0% in 2020. The presence of a large number of market players, improved research to identify suitable drug candidates, significant investment by large players to improve the development of newer formulations, and improved rate of diagnosis and treatment are the factors boosting the regional market growth.

Asia Pacific is expected to witness the highest growth during the forecast period. A rise in the geriatric population, the growth of the pharmaceutical industry, and an enormous rise in domestic players are likely to boost the regional market growth.

Key Players

  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • GlaxoSmithKline plc.
  • Indivior Pharmaceuticals
  • Generex Biotechnology
  • Catalent
  • ARx LLC
  • BioDelivery Sciences International, Inc.
  • Cynapsus Therapeutics Inc.
  • Endo Pharmaceuticals plc

Market Segmentation

  • By Type
    • Sublingual Films
    • Buccal Tablets and Lozenges
    • Oral Sprays
  • By Application
    • Pain Management
    • Smoking Cessation
    • Angina Pectoris
    • Others
  • By End-user
    • Hospitals
    • Ambulatory Centers
    • Others
  • Regional
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Norway
      • Sweden
      • Russia
    • Asia Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Thailand
    • Latin America
      • Brazil
      • Mexico
      • Argentina
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • Turkey
      • UAE

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38999

Reasons to Purchase this Report:

– Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
– Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
– Market value USD Million and volume Units Million data for each segment and sub-segment
– Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
– Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

Table of Contents

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Buccal Drug Delivery Market, By Type

7.1.  Buccal Drug Delivery Market, by Type, 2021-2030

7.1.1.    Sublingual Films

7.1.1.1.        Market Revenue and Forecast (2017-2030)

7.1.2.    Buccal Tablets and Lozenges

7.1.2.1.        Market Revenue and Forecast (2017-2030)

7.1.3.    Oral Sprays

7.1.3.1.        Market Revenue and Forecast (2017-2030)

Chapter 8.  Global Buccal Drug Delivery Market, By Application

8.1.  Buccal Drug Delivery Market, by Application, 2021-2030

8.1.1.    Pain Management

8.1.1.1.        Market Revenue and Forecast (2017-2030)

8.1.2.    Smoking Cessation

8.1.2.1.        Market Revenue and Forecast (2017-2030)

8.1.3.    Angina Pectoris

8.1.3.1.        Market Revenue and Forecast (2017-2030)

8.1.4.    Others

8.1.4.1.        Market Revenue and Forecast (2017-2030)

Chapter 9.  Global Buccal Drug Delivery Market, By End User

9.1.  Buccal Drug Delivery Market, by End User, 2021-2030

9.1.1.    Hospitals

9.1.1.1.        Market Revenue and Forecast (2017-2030)

9.1.2.    Ambulatory Centers

9.1.2.1.        Market Revenue and Forecast (2017-2030)

9.1.3.    Others

9.1.3.1.        Market Revenue and Forecast (2017-2030)

Chapter 10.      Global Buccal Drug Delivery Market, Regional Estimates and Trend Forecast

10.1.        North America

10.1.1.  Market Revenue and Forecast, by Type (2017-2030)

10.1.2.  Market Revenue and Forecast, by Application (2017-2030)

10.1.3.  Market Revenue and Forecast, by End User (2017-2030)

10.1.4.  U.S.

10.1.4.1.      Market Revenue and Forecast, by Type (2017-2030)

10.1.4.2.      Market Revenue and Forecast, by Application (2017-2030)

10.1.4.3.      Market Revenue and Forecast, by End User (2017-2030)

10.1.5.  Rest of North America

10.1.5.1.      Market Revenue and Forecast, by Type (2017-2030)

10.1.5.2.      Market Revenue and Forecast, by Application (2017-2030)

10.1.5.3.      Market Revenue and Forecast, by End User (2017-2030)

10.2.        Europe

10.2.1.  Market Revenue and Forecast, by Type (2017-2030)

10.2.2.  Market Revenue and Forecast, by Application (2017-2030)

10.2.3.  Market Revenue and Forecast, by End User (2017-2030)

10.2.4.  UK

10.2.4.1.      Market Revenue and Forecast, by Type (2017-2030)

10.2.4.2.      Market Revenue and Forecast, by Application (2017-2030)

10.2.4.3.      Market Revenue and Forecast, by End User (2017-2030)

10.2.5.  Germany

10.2.5.1.      Market Revenue and Forecast, by Type (2017-2030)

10.2.5.2.      Market Revenue and Forecast, by Application (2017-2030)

10.2.5.3.      Market Revenue and Forecast, by End User (2017-2030)

10.2.6.  France

10.2.6.1.      Market Revenue and Forecast, by Type (2017-2030)

10.2.6.2.      Market Revenue and Forecast, by Application (2017-2030)

10.2.6.3.      Market Revenue and Forecast, by End User (2017-2030)

10.2.7.  Rest of Europe

10.2.7.1.      Market Revenue and Forecast, by Type (2017-2030)

10.2.7.2.      Market Revenue and Forecast, by Application (2017-2030)

10.2.7.3.      Market Revenue and Forecast, by End User (2017-2030)

10.3.        APAC

10.3.1.  Market Revenue and Forecast, by Type (2017-2030)

10.3.2.  Market Revenue and Forecast, by Application (2017-2030)

10.3.3.  Market Revenue and Forecast, by End User (2017-2030)

10.3.4.  India

10.3.4.1.      Market Revenue and Forecast, by Type (2017-2030)

10.3.4.2.      Market Revenue and Forecast, by Application (2017-2030)

10.3.4.3.      Market Revenue and Forecast, by End User (2017-2030)

10.3.5.  China

10.3.5.1.      Market Revenue and Forecast, by Type (2017-2030)

10.3.5.2.      Market Revenue and Forecast, by Application (2017-2030)

10.3.5.3.      Market Revenue and Forecast, by End User (2017-2030)

10.3.6.  Japan

10.3.6.1.      Market Revenue and Forecast, by Type (2017-2030)

10.3.6.2.      Market Revenue and Forecast, by Application (2017-2030)

10.3.6.3.      Market Revenue and Forecast, by End User (2017-2030)

10.3.7.  Rest of APAC

10.3.7.1.      Market Revenue and Forecast, by Type (2017-2030)

10.3.7.2.      Market Revenue and Forecast, by Application (2017-2030)

10.3.7.3.      Market Revenue and Forecast, by End User (2017-2030)

10.4.        MEA

10.4.1.  Market Revenue and Forecast, by Type (2017-2030)

10.4.2.  Market Revenue and Forecast, by Application (2017-2030)

10.4.3.  Market Revenue and Forecast, by End User (2017-2030)

10.4.4.  GCC

10.4.4.1.      Market Revenue and Forecast, by Type (2017-2030)

10.4.4.2.      Market Revenue and Forecast, by Application (2017-2030)

10.4.4.3.      Market Revenue and Forecast, by End User (2017-2030)

10.4.5.  North Africa

10.4.5.1.      Market Revenue and Forecast, by Type (2017-2030)

10.4.5.2.      Market Revenue and Forecast, by Application (2017-2030)

10.4.5.3.      Market Revenue and Forecast, by End User (2017-2030)

10.4.6.  South Africa

10.4.6.1.      Market Revenue and Forecast, by Type (2017-2030)

10.4.6.2.      Market Revenue and Forecast, by Application (2017-2030)

10.4.6.3.      Market Revenue and Forecast, by End User (2017-2030)

10.4.7.  Rest of MEA

10.4.7.1.      Market Revenue and Forecast, by Type (2017-2030)

10.4.7.2.      Market Revenue and Forecast, by Application (2017-2030)

10.4.7.3.      Market Revenue and Forecast, by End User (2017-2030)

10.5.        Latin America

10.5.1.  Market Revenue and Forecast, by Type (2017-2030)

10.5.2.  Market Revenue and Forecast, by Application (2017-2030)

10.5.3.  Market Revenue and Forecast, by End User (2017-2030)

10.5.4.  Brazil

10.5.4.1.      Market Revenue and Forecast, by Type (2017-2030)

10.5.4.2.      Market Revenue and Forecast, by Application (2017-2030)

10.5.4.3.      Market Revenue and Forecast, by End User (2017-2030)

10.5.5.  Rest of LATAM

10.5.5.1.      Market Revenue and Forecast, by Type (2017-2030)

10.5.5.2.      Market Revenue and Forecast, by Application (2017-2030)

10.5.5.3.      Market Revenue and Forecast, by End User (2017-2030)

Chapter 11.  Company Profiles

11.1.              Teva Pharmaceutical Industries Ltd.

11.1.1.  Company Overview

11.1.2.  Product Offerings

11.1.3.  Financial Performance

11.1.4.  Recent Initiatives

11.2.              Pfizer Inc.

11.2.1.  Company Overview

11.2.2.  Product Offerings

11.2.3.  Financial Performance

11.2.4.  Recent Initiatives

11.3.              GlaxoSmithKline plc.

11.3.1.  Company Overview

11.3.2.  Product Offerings

11.3.3.  Financial Performance

11.3.4.  Recent Initiatives

11.4.              Indivior Pharmaceuticals

11.4.1.  Company Overview

11.4.2.  Product Offerings

11.4.3.  Financial Performance

11.4.4.  Recent Initiatives

11.5.              Generex Biotechnology

11.5.1.  Company Overview

11.5.2.  Product Offerings

11.5.3.  Financial Performance

11.5.4.  Recent Initiatives

11.6.              Catalent

11.6.1.  Company Overview

11.6.2.  Product Offerings

11.6.3.  Financial Performance

11.6.4.  Recent Initiatives

11.7.              ARx LLC

11.7.1.  Company Overview

11.7.2.  Product Offerings

11.7.3.  Financial Performance

11.7.4.  Recent Initiatives

11.8.              BioDelivery Sciences International, Inc.

11.8.1.  Company Overview

11.8.2.  Product Offerings

11.8.3.  Financial Performance

11.8.4.  Recent Initiatives

11.9.              Cynapsus Therapeutics Inc.

11.9.1.  Company Overview

11.9.2.  Product Offerings

11.9.3.  Financial Performance

11.9.4.  Recent Initiatives

11.10.           Endo Pharmaceuticals plc

11.10.1.               Company Overview

11.10.2.               Product Offerings

11.10.3.               Financial Performance

11.10.4.               Recent Initiatives

Chapter 12.  Research Methodology

12.1.              Primary Research

12.2.              Secondary Research

12.3.              Assumptions

Chapter 13.  Appendix

13.1.              About Us

13.2.              Glossary of Terms

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38999

Contact Us:

Vision Research Reports

Call: +1 9197 992 333

Email: sales@visionresearchreports.com